Phase II corneal health clinical program initiated for pharmaceutical platform
March 16th 2022Glaukos Corp’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.
Pilot project aims to overcome inequalities in glaucoma diagnoses
March 10th 2022Many low- and middle-income countries lack resources for managing eye health. A pilot project aims to reduce the number of people going blind from untreated glaucoma by raising awareness and increasing engagement with screening and follow-up.
Ophthalmology and the climate crisis: Time to take responsibility
March 3rd 2022The healthcare sector has high greenhouse gas emissions, to which ophthalmology is a significant contributor. Reducing waste, reusing instruments and medication and increasing our use of telemedicine can all contribute to reducing the carbon footprint of our specialty.
The retina may reveal risk of Alzheimer disease in middle age
February 19th 2022Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.